In a pilot trial where two patients with synovial sarcoma were treated with an addition of IFNγ and IL-2 to the combined cyclophosphamide and adoptive T cell transfer therapy, although one patient showed significant tumour regression, the other suffered fatal histiocytic myocarditis [106]. This evidence concerns the gene IFNG and neoplasm.